HC Wainwright Issues Optimistic Estimate for SLNO Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Soleno to $0.93 (from $0.88), reiterated a Buy rating and set a $100 price target while forecasting Q2 2026 EPS of $1.02 and FY2027 EPS of $7.50.
• The analyst landscape is mixed—one Strong Buy, 12 Buy, 1 Hold and 1 Sell—giving a MarketBeat average rating of "Moderate Buy" and an average price target of $106.85.
• Soleno recently beat expectations, reporting $0.80 EPS (vs. $0.64 est.) and $91.7M revenue, even as the stock trades around $38 with a high P/E (~165.8) and a market cap near $1.97B.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Soleno Therapeutics in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.93 per share for the quarter, up from their previous estimate of $0.88. HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q2 2026 earnings at $1.02 EPS and FY2027 earnings at $7.50 EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Wells Fargo & Company decreased their target price on Soleno Therapeutics from $114.00 to $110.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Wall Street Zen lowered shares of Soleno Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. Zacks Research lowered shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 3rd. Finally, Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $106.85.

Soleno Therapeutics Price Performance

Soleno Therapeutics stock opened at $38.13 on Thursday. Soleno Therapeutics has a 1 year low of $32.63 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. The firm has a 50 day moving average price of $41.98 and a 200 day moving average price of $52.52. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 165.79 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analysts' expectations of $88.55 million.

Hedge Funds Weigh In On Soleno Therapeutics

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock worth $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics during the second quarter valued at approximately $25,000. Avanza Fonder AB raised its position in shares of Soleno Therapeutics by 11.2% during the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company's stock worth $148,000 after purchasing an additional 323 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Soleno Therapeutics by 11.9% in the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company's stock worth $216,000 after purchasing an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in Soleno Therapeutics by 2.4% during the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company's stock valued at $1,055,000 after purchasing an additional 360 shares during the period. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.